Martyn Greenacre

From 1997-2001 he was CEO of Delsys Pharmaceutical Corp., a drug delivery company. From 1993-1997 he was president and CEO of Zynaxis, a biopharmaceutical company. He joined SmithKline & French in 1973, eventually rising to chairman, Europe for SmithKline Beecham Pharmaceutical Co. from 1989-1992. Also joining the NeoStem board is the company’s chief medical officer, Andrew L. Pecora, M.D. also is a director of Curis Inc.

  • 2012 First Quarter

Added to: NeoStem Inc. - New York, NY

NeoStem is a developer and manufacturer of cell therapies. Revenues are $74 million.